Buy, Sell or Hold: Bellus Health (BLU-X) — Stock Predictions at Stockchase

0.00

0.00 (0.00%) 1d

Showing 1 to 2 of 2 entries

RISKY BUY

The outlook is still quite good. People who use their competing chronic cough treatment lose their sense of taste. They are applying now for their drug's use for other conditions.

biotechnology / pharmaceutical

RISKY BUY

A pharma company working on a new drug for chronic cough. Early testing has produced good effectiveness and no nasty side effects. Tests should be completed within the year. He believes 60 to 300 patients are being tested. They have great potential. A speculative buy. It may become a takeover target.

biotechnology / pharmaceutical

Showing 1 to 2 of 2 entries

Bellus Health(BLU-X) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Bellus Health is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Bellus Health(BLU-X) Frequently Asked Questions

What is Bellus Health stock symbol?

Bellus Health is a OTC stock, trading under the symbol BLU-X on the (). It is usually referred to as or BLU-X

Is Bellus Health a buy or a sell?

In the last year, there was no coverage of Bellus Health published on Stockchase.

Is Bellus Health a good investment or a top pick?

Bellus Health was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Bellus Health.

Why is Bellus Health stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Bellus Health worth watching?

0 stock analysts on Stockchase covered Bellus Health In the last year. It is a trending stock that is worth watching.

What is Bellus Health stock price?

On , Bellus Health (BLU-X) stock closed at a price of $.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.